

## Continuing Medical Education

### How to Effectively Use Methotrexate in Rheumatoid Arthritis?☆

Samuel Hernandez-Baldizon

Servicio de Reumatología, Hospital de Cruces, Baracaldo, Vizcaya, Spain

#### ARTICLE INFO

##### Article history:

Received 5 November 2010

Accepted 27 January 2011

Available online 11 November 2011

##### Keywords:

Rheumatoid arthritis

Methotrexate

Clinical practice

Dose

Side effects

Adverse reactions

#### ABSTRACT

Methotrexate (MTX) is the first choice disease modifying anti-rheumatic drugs for rheumatoid arthritis. In spite of its generalized use by rheumatologists worldwide, there is a general lack of agreement regarding the route of administration, the start-up dose and the way to increase the same. In this article, we propose a simplified outline for the use of the drug that should be individualized, based on its pharmacological aspects, guidelines and recommendations published in high impact factor journals during the past few years. Adverse reactions and side effects, as well as their follow up are also reviewed.

© 2010 Elsevier España, S.L. All rights reserved.

### ¿Cómo hacer buen uso del metotrexato en artritis reumatoide?

#### RESUMEN

El metotrexato (MTX) es el fármaco modificador de la enfermedad de primera elección en artritis reumatoide. A pesar del uso casi generalizado por reumatólogos en todo el mundo, hay mucha discordancia entre la forma de iniciar la dosis, la vía de administración y la forma de realizar el incremento de dosis. En este artículo se planteamos un esquema simplificado del uso de este fármaco a individualizar en cada caso, basado en los aspectos farmacológicos, guías y protocolos de manejo publicados en revistas de impacto de nuestra especialidad en los últimos años. Se revisa además las reacciones adversas y efectos secundarios y cómo realizar el seguimiento de éstos.

© 2010 Elsevier España, S.L. Todos los derechos reservados.

##### Palabras clave:

Artritis reumatoide

Metotrexato

Práctica clínica

Dosis

Efectos secundarios

Reacciones adversas

Rheumatoid arthritis (RA) is an autoimmune systemic disease characterized primarily by symmetric, episodic, chronic, erosive, deforming polyarthritis that produces long-term joint disability if uncontrolled. Currently, methotrexate (MTX) is the disease-modifying drug most commonly used in RA and the first treatment choice.<sup>1–3</sup> Despite its almost universal therapeutic application, there is much disagreement on the part of rheumatologists in terms of the starting dose, how to increase it and the route of administration (Fig. 1).

In this article we propose a simplified clinical setting which may serve to identify general recommendation for each individual case. Our proposal is based on the analysis of review articles,

meta-analysis, consensus and clinical practice guidelines published in the last five years in influential journals of our specialty.

#### How Does It Work?

MTX is an antimetabolite that competitively inhibits dihydrofolate reductase. This enzyme participates in the formation of tetrahydrofolate, necessary for the formation of the nucleoside thymidine, required for the synthesis of DNA, RNA, thymidylate and proteins. It partially inhibits the immune response<sup>4</sup> and, although through a poorly understood mechanism, autoimmune joint inflammation is reduced in the long term.

#### What Pharmacological Aspects Must Be Taken into Account?

Oral absorption of MTX is dose dependent and varies significantly according to intestinal transit. Meals, diarrhea and

☆ Please, cite this article as: Hernandez-Baldizon S. ¿Cómo hacer buen uso del metotrexato en artritis reumatoide? Reumatol Clin. 2012;8(1):42–45.

E-mail address: [samuel.hernandezbaldizon@osakidetza.net](mailto:samuel.hernandezbaldizon@osakidetza.net)




Fig. 1. Onset and dose increase.

non-absorbable antibiotics decrease its absorption, while constipation increases it. The oral mean bioavailability is 33% and parenteral is 77%. Once in the serum, 50% circulates bound to proteins, with a half life of 3–10 h. Excretion is 90% renal and 10% gastrointestinal.<sup>5</sup> These are issues that we must take into account when assessing the risk of adverse reactions and side effects of the drug, as their frequency increases in proportion to plasma levels (Table 1).

### When to Start Treatment?

One should begin treatment with disease modifying drugs as soon as the diagnosis is carried out.<sup>2</sup> Diagnosis is mostly based on the history and physical examination, and less on the classification criteria. The patient will usually complain of pain, morning stiffness and swelling. Physical examination reveals symmetrical swelling and joint tenderness. However, these findings are not unique to RA in its early stage and a differential diagnosis is necessary. The RA classification criteria published in September 2010 by the ACR/EULAR<sup>6</sup> aim to classify patients who may benefit from treatment in the initial stages of the disease.

### What Tests Should Be Performed Before Onset of Treatment?

Patients should be screened for assessment of potential toxicity risk factors (such as alcohol) and CBC, CRP and ESR, serum creatinine, transaminases, albumin, antibodies against hepatitis B and C, rheumatoid factor, anti cyclic citrullinated peptide antibodies, lipid profile, pregnancy test and chest, hands and feet X-rays carried out.<sup>1,3</sup> The application of the vaccine against pneumococcus and seasonal influenza virus<sup>1</sup> is also recommended. HIV serology<sup>3</sup> should also be assessed (Table 2).

The patient and the physician should assess pain and/or global disease activity scores (visual analog scale of 0–10). The doctor

Table 1  
Main Interactions of Methotrexate.

Amoxicillin	Indomethacin
Trimethoprim	Nabumethone
Triamterene	Doxycycline
Omeprazole	Penicillin G
Tamoxifen	Flurbiprofen
Ketoprofen	Aspirin
Clotrimoxazole	Tazobactam
Piroxicam	Sulphamethoxazole
Diflunisal	Mercaptopurine
Ketorolac	Etodolac
Diclofenac	Acyclovir
Piperacillyn	Phenylbutazone
Naproxen	Citarabin
	Kanamycin

Modified from <http://www.drugs.com/methotrexate.html>.

Table 2  
Tests That Must Be Performed Prior to Treatment.

Hemogram
Transaminases
CRP and ESR
Plasma creatinine
Hepatitis B and C serology
Plasma albumin
Simple X-rays of hands, feet and thorax

should perform a 28 joint count calculating a standard index of disease activity such as the DAS28. If positive for activity (DAS28 greater than 3), treatment is indicated.

### What Dose Should Be Used at Onset of Treatment?

There are multiple ways to approach treatment and each rheumatologist has his or her own way home, especially with regard to the route of administration and increasing the therapeutic dose. Here, we refer to treatment consensus and systematic reviews.<sup>1–3,7</sup> Traditionally, the recommended starting dose has been of 7.5–10 mg weekly for 4 weeks associated with folic acid in doses of 5–10 mg the day after taking MTX. Subsequently, a progressive increase between 2.5 and 5 mg every 2–4 weeks until a dose of 25 mg is reached between 3 and 6 months from the onset of treatment,<sup>5</sup> since high doses of 25–30 mg weekly are more effective as disease-modifying than 10–15 mg<sup>3</sup>.

The starting dose recommended by GUIPCAR-SER typically varies between 7.5 and 15 mg weekly orally (4–6 tablets of 2.5 mg).<sup>1</sup> After 15 mg it is recommended to use the intravenous route to improve bioavailability (33% oral vs 77% parenteral).<sup>1</sup>

However, a systematic review of the literature on the use of MTX<sup>3</sup> recommended starting treatment with 10–15 mg orally, increasing 5 mg every 2 weeks up to 20–30 mg, depending on clinical response and tolerance. Parenteral administration of the drug should be considered in the case of poor response or intolerance.

Furthermore, the effectiveness of drug response, including a joint count, should be monitored,<sup>8</sup> for example using the DAS28, which has been validated and reviewed for this purpose in recent years.<sup>9</sup>

### What Adverse Reactions and Side Effects Can We Foresee?

The evidence of risk factors for severe MTX toxicity suggests that a creatinine clearance of less than 79 ml/min increases the risk of pulmonary toxicity, and severe hypoalbuminemia in these patients is associated with liver and lung toxicity.<sup>10,11</sup> Abnormalities on chest x-rays, rather than respiratory function tests, are predictive of an increased risk of MTX pneumonitis.<sup>12,13</sup> The subgroups of patients with additional risk of developing liver failure secondary to the drug are mainly obese, diabetics and patients with viral or alcoholic hepatitis.<sup>14,15</sup> Adding this observational evidence to that of experts on the contraindications of the drug in randomized clinical trials in the last 15 years, it is not recommended to use MTX in the presence of significant renal disease, liver disease, leukopenia of less than 3000/mm<sup>3</sup>, thrombocytopenia of less than 100,000/mm<sup>3</sup>, age over 70 years, malignancy, pregnancy or fertility problems, a history of substance abuse/alcoholism, chronic lung disease and acute or chronic systemic infections (Table 3).

The toxicity of oral MTX is dose dependent, and initial doses of 20 mg have shown greater efficiency but a higher incidence of intolerance. Initial doses of 12.5–20 mg weekly compared to oral doses of 5–10 mg have shown to be more effective without increasing toxicity.<sup>16</sup> Regarding administration, the parenteral route has proven more effective in retrospective studies and shows

**Table 3**  
Precautions and Contraindications.

One must clinically evaluate:
Significant renal disease
Liver disease
Leukopenia, neutropenia or low platelets
Pregnancy or fertility problems
Lung disease
A history of drug use
Acute or chronic systemic infection

less gastrointestinal adverse reactions most probably due to greater bioavailability.<sup>17,18</sup>

### How and Why Folic Acid Is Used in These Patients?

We recommend the prescription of at least 5 mg of folic acid week. Folic acid supplementation significantly reduced liver and gastrointestinal toxicity without affecting efficacy.<sup>19</sup> Similarly, doses higher than 5 mg weekly of folinic acid were associated with a greater number of swollen joints and, therefore, a decreased efficacy of the drug for disease control.<sup>20,21</sup>

### What Controls Should Be Used for Safety Monitoring?

When you start MTX and increase its dose, ALT and AST, creatinine and CBC controls should be performed every month or 6 weeks until the maintenance dose is reached and then every 1–3 months, given that high levels of AST have been linked to higher incidence of hepatotoxicity in RA. Risk factors for toxicity and adverse reactions should be assessed in each visit.<sup>3</sup> Creatinine clearance should be monitored, since renal function abnormalities are associated with increased lung toxicity. The CBC should be used to monitor the possibility of blood disorders (Table 4).

### In What Cases Should MTX Be Discontinued Due to Toxicity/Adverse Reactions?

MTX should be discontinued if AST exceeds more than three times the upper limit of normal. However, it may be reintroduced at a lower dose once normal. If the AST/ALT is more than three times the normal limit, the dose should be adjusted. If after discontinuation of MTX, AST/ALT remains more than three times the upper limit of normal, diagnostic testing should be conducted<sup>3</sup> to justify it.

The evidence suggests that elevations of ALT are common but transient, and also finds that significant multiple ALT elevations are more indicative of a liver biopsy than a single reading. Cirrhosis/liver fibrosis secondary to MTX are rare. Experts recommend ruling out other causes of elevated ALT, such as NSAIDs, obesity and chronic alcohol intake before performing a liver biopsy, if enzyme elevation persists after cessation of the drug.<sup>3</sup>

### Is Long-term Treatment of Rheumatoid Arthritis With Methotrexate Safe?

Based on its acceptable safety profile, MTX is suitable for long-term use. Patients with RA have increased mortality compared to the population in general.<sup>22</sup> However, patients with RA treated with MTX had a lower incidence of mortality than patients with RA

**Table 4**  
Safety Control and Monitoring.

ALT/AST	Creatinine Clearance	Hemogram
Liver toxicity	Lung toxicity	Blood abnormalities

without MTX and less cardiovascular mortality in a large prospective study with a follow up of 6 years.<sup>23</sup> In addition, in two case-control studies, MTX was shown not to be a risk factor and even was a protective factor for cardiovascular disease. In the long term, MTX was not associated with a higher rate of serious infections, including herpes zoster.

Although patients with RA have an increased risk of lymphoma compared with the general population, the risk of MTX independent from the evidence of RA is inconclusive because the studies did not address RA as the reference population and the risk was not adjusted for the severity of the disease. Five case-reports suggest that MTX may be associated with lymphoproliferative disease related to Epstein-Barr virus and reported the regression of disease after the withdrawal of the drug.<sup>24</sup>

### In Patients Without Prior Treatment With Disease Modifying Drugs, Can It Be Used as Monotherapy or Should It Be Combined?

The effectiveness/toxicity balance of MTX alone favors the combination of MTX with another disease modifying drug. MTX should be considered as the “anchor” drug due to the lack of effectiveness of MTX alone. In a meta-analysis of 20 randomized clinical trials, with patients stratified with respect to previous use of disease modifying drugs and with a poor response to monotherapy, MTX monotherapy was more effective in naïve patients than those with insufficient response. That said, this balance of toxicity/effectiveness of monotherapy does not lessen the fact of a greater overall efficacy of MTX in combination with another disease modifying drug.

### Should MTX Be Discontinued Before Major Surgery?

There is only one report on the use of MTX in the perioperative period of orthopedic surgery. There was no evidence found of an increased incidence of infection compared to the control group. However, no studies exist evaluating the effect of MTX during this period.<sup>3</sup>

### Should Methotrexate Be Discontinued Before Conception?

MTX should be discontinued at least 3 months before conception in men and women planning a pregnancy. It should not be used during pregnancy or while breastfeeding.

Six studies have evaluated the use of MTX during pregnancy/lactation with 101 exposed during pregnancy and before conceiving. There were 18 cases of abortions without naming the underlying cause and 5 birth defects. However, no studies have evaluated the use of MTX in men in terms of the rate of abortions/birth defects, in male and female fertility or in breast-feeding newborns. However, expert opinion recommends stopping the drug at least 3 months before a planned pregnancy and avoiding its use during pregnancy and lactation.

Given the above, we conclude that MTX is an effective drug that helps control RA. An analytical and clinical control during its use is important to minimize the risk of a serious complication.

### References

- Tornero Molina J, Sanmartí Sala R, Rodríguez Valverde V, Martín Mola E, Marengo de la Fuente JL, Gonzalez Alvaro I. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. *Reumatol Clin.* 2010;6:23–36.
- Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. *Ann Rheum Dis.* 2010;69:964–75.

3. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Ann Rheum Dis.* 2009;68:1086–9.
4. Rajagopalan PTR, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG. Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics. *PNAS.* 2002;99:13481–6.
5. Available from: <http://www.drugs.com/methotrexate.html>.
6. Aletaha D, Neogi T, Siman AJ, Funovits J, Felson DT, Bingham III CO, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum.* 2010;62:2569–81.
7. Visser K, Van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. *Ann Rheum Dis.* 2009;68:1094–9.
8. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet.* 2004;364:263–9.
9. Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis.* 2010;69:631–7.
10. Alarcon GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. *Methotrexate-Lung Study Group. Ann Intern Med.* 1997;127:356–64.
11. Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. *J Rheumatol.* 1995;22:1043–7.
12. Beyeler C, Jordi B, Gerber NJ, Im Hof V. Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. *Br J Rheumatol.* 1996;35:446–52.
13. Shergy WJ, Polisson RP, Caldwell DS, Rice JR, Pisetsky DS, Allen NB. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. *Am J Med.* 1988;85:771–4.
14. Phillips CA, Cera PJ, Mangan TF, Newman ED. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. *J Rheumatol.* 1992;19:229–33.
15. Schnabel A, Reinhold-Keller E, Willmann V, Gross WL. Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. *Rheumatol Int.* 1994;14:33–8.
16. Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. *J Rheumatol.* 1993;20:1845–9.
17. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, Van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. *J Rheumatol.* 2004;31:645–8.
18. Katchamart W, Ortiz Z, Shea B, Tugwell P, Bombardier C. Folic acid and folic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (an update systematic review and metaanalysis). *Arthritis Rheum.* 2008;58 Suppl.:S473.
19. Hanrahan PS, Russell AS. Concurrent use of folic acid and methotrexate in rheumatoid arthritis. *J Rheumatol.* 1988;15:1078–80.
20. Joyce DA, Will RK, Hoffman DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folic acid. *Ann Rheum Dis.* 1991;50:913–4.
21. Alarcon GS, Tracy IC, Strand GM, Singh K, Macaluso M. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. *Ann Rheum Dis.* 1995;54:708–12.
22. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. *Lancet.* 2002;359:1173–7.
23. Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda JI, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. *J Rheumatol.* 2007;34:322–31.
24. Katchamart W, Trudeau J, Phumethum V, Bombardier C. The efficacy and toxicity of methotrexate (MTX) monotherapy vs MTX combination therapy with non-biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and metaanalysis. *Ann Rheum Dis.* 2009;68:1012–105.